STOCK TITAN

LB Pharmaceuticals (LBRX) director awarded 10,000 stock options at $27.95

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

LB Pharmaceuticals Inc. director Garland J. Scott received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $27.95 per share and expire on June 2, 2036. This is a compensation-related award, not an open-market purchase or sale.

According to the terms, 100% of the shares underlying the option vest on the earlier of June 3, 2027 or the date of the company’s next annual meeting of stockholders, subject to Scott’s continuous service through the vesting date. Following the grant, Scott holds 10,000 stock options directly.

Positive

  • None.

Negative

  • None.
Insider Garland J. Scott
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 10,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 10,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 10,000 options Stock Option (Right to Buy) granted to director
Exercise price $27.95 per share Price to buy underlying LB Pharmaceuticals common stock
Expiration date June 2, 2036 Options lapse if not exercised by this date
Vesting trigger date June 3, 2027 Vests on earlier of this date or next annual meeting
Underlying shares 10,000 shares Common stock underlying the option grant
Post-transaction derivative holdings 10,000 options Total options held directly after this grant
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 27.9500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"100% of the shares underlying the option vest on the earlier of"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting of stockholders financial
"the date of the Issuer's next annual meeting of stockholders"
expiration date financial
"expiration_date: 2036-06-02T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Garland J. Scott

(Last)(First)(Middle)
C/O LB PHARMACEUTICALS INC
ONE PENNSYLVANIA PLAZA, SUITE 1025

(Street)
NEW YORK NEW YORK 10119

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
LB PHARMACEUTICALS INC [ LBRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$27.9506/03/2026A10,000 (1)06/02/2036Common Stock10,000$010,000D
Explanation of Responses:
1. 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
/s/ Marc Panoff, Attorney-in-Fact06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did LB PHARMACEUTICALS INC (LBRX) report for Garland J. Scott?

LB Pharmaceuticals reported that director Garland J. Scott received a grant of stock options for 10,000 shares of common stock as compensation. The award is a non-cash grant and does not represent an open-market purchase or sale of LBRX shares.

What is the exercise price of Garland J. Scott’s new LB PHARMACEUTICALS (LBRX) stock options?

The granted stock options have an exercise price of $27.95 per share. This means Scott can buy up to 10,000 LB Pharmaceuticals common shares at $27.95, once the options vest and before they expire on June 2, 2036.

When do Garland J. Scott’s LB PHARMACEUTICALS (LBRX) options vest?

All 10,000 options vest 100% on the earlier of June 3, 2027 or the date of LB Pharmaceuticals’ next annual meeting of stockholders. Vesting is subject to Scott’s continuous service with the company through the applicable vesting date.

When do the newly granted LB PHARMACEUTICALS (LBRX) stock options expire?

The stock options granted to Garland J. Scott expire on June 2, 2036. After that expiration date, any unexercised options become worthless, so they must be exercised, if at all, between vesting and this expiration date.

Did Garland J. Scott buy or sell LB PHARMACEUTICALS (LBRX) shares in this Form 4?

No open-market buy or sell occurred. The Form 4 shows a compensation-related grant of stock options (code A) giving Scott the right to buy 10,000 shares at $27.95, subject to vesting and future exercise, rather than an immediate share transaction.

How many LB PHARMACEUTICALS (LBRX) stock options does Garland J. Scott hold after this grant?

After the reported transaction, Garland J. Scott holds 10,000 stock options directly. These options each relate to one share of LB Pharmaceuticals common stock and are subject to vesting and an exercise price of $27.95 per share until June 2, 2036.